Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Can-Fite BioPharma Ltd. (CANF)

0.74425   -0.063 (-7.79%) 09-24 14:46
Open: 0.83 Pre. Close: 0.8071
High: 0.8144 Low: 0.7401
Volume: 163,834 Market Cap: 20(M)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.83 - 0.84 0.84 - 0.84
Low: 0.73 - 0.73 0.73 - 0.74
Close: 0.74 - 0.74 0.74 - 0.75

Technical analysis

as of: 2022-09-23 4:22:50 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.05     One year: 1.16
Support: Support1: 0.74    Support2: 0.61
Resistance: Resistance1: 0.9    Resistance2: 1
Pivot: 0.87
Moving Average: MA(5): 0.81     MA(20): 0.89
MA(100): 0.88     MA(250): 1.09
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 10.8     %D(3): 14.4
RSI: RSI(14): 29.7
52-week: High: 2.59  Low: 0.74
Average Vol(K): 3-Month: 148 (K)  10-Days: 65 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CANF ] has closed below the lower bollinger band by 16.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CANF ] is to continue within current trading range. Bollinger Bands are 26.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 23 Sep 2022
Ian Incoming? South Florida in Forecast Cone for Potential Hurricane - Miami New Times

Fri, 23 Sep 2022
Miami Names Park After Late Business Magnate, Anti-Castro Militant - Miami New Times

Fri, 23 Sep 2022
2022-09-23 | NYSEAM:CANF | Press Release | Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stockhouse

Mon, 12 Sep 2022
Can Fite Biofarma (AMEX:CANF) – Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved - Benzinga

Wed, 07 Sep 2022
Police report details chaos of 75 to 100 people fighting at Canfield Fair - WFMJ

Tue, 23 Aug 2022
CANF stock gains as compassionate use of liver cancer therapy expands (NYSE:CANF) - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 20 (M)
% Held by Insiders 2.005e+007 (%)
% Held by Institutions 0 (%)
Shares Short 413 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.236e+007
EPS Est Next Qtl -0.08
EPS Est This Year -0.28
EPS Est Next Year -0.62
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 547.8
Return on Equity (ttm) -55.3
Qtrly Rev. Growth 799000
Gross Profit (p.s.) 11.24
Sales Per Share -76.06
EBITDA (p.s.) 451479
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 2.62

Stock Dividends

Dividend 0
Forward Dividend 4.46e+006
Dividend Yield 0%
Dividend Pay Date 2019-05-09
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.